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Protein oligomers have been implicated as toxic agents in a wide range of amyloid-related dis-
eases. Yet it has remained unsolved whether the oligomers are a necessary step in the formation of
amyloid fibrils, or just a dangerous by-product. Analogously, it has not been resolved if the amyloid
nucleation process is a classical one-step nucleation process, or a two-step process involving pre-
nucleation clusters. We use coarse-grained computer simulations to study the effect of non-specific
attractions between peptides on the primary nucleation process underlying amyloid fibrillization.
We find that for peptides that do not attract, the classical one-step nucleation mechanism is pos-
sible, but only at non-physiologically high peptide concentrations. At low peptide concentrations,
which mimic the physiologically relevant regime, attractive inter-peptide interactions are essential
for fibril formation. Nucleation then inevitably takes place through a two-step mechanism involving
prefibrillar oligomers. We show that oligomers not only help peptides meet each other, but create an
environment that facilitates the conversion of monomers into the β-sheet rich form characteristic of
fibrils. Nucleation typically does not proceed via the most prevalent oligomers, but via an oligomer
size that is only observed in rare fluctuations, which is why such aggregates might be hard to cap-
ture experimentally. Finally, we find that the nucleation of amyloid fibrils cannot be described by
classical nucleation theory: in the two-step mechanism the critical nucleus size increases both with
an increase in concentration and in the inter-peptide interactions, in direct contrast with predictions
from classical nucleation theory.
Significance Statement
The assembly of normally soluble proteins into large
fibrils, known as amyloid aggregation, is associated with
a range of pathologies. Prefibrillar protein oligomers, not
the grown fibers, are believed to be the main toxic agents.
It is unresolved if these oligomers are necessary for fib-
ril assembly, or just a dangerous by-product. We show
by using computer simulations that at physiological con-
centrations, amyloid formation must proceed via a two-
step process including prefibrillar oligomers. We find that
there is an optimal oligomeric size for amyloid nucleation,
and that classical nucleation theory cannot be applied to
this process. Formation of oligomers and hence fibrils,
is controlled by the strength of non-specific attractions,
whose weakening may be crucial in preventing amyloid
aggregation.
Introduction
During the process of amyloid formation, normally sol-
uble proteins assemble into fibrils that are enriched in
β-sheet content, and have diameters of a few nanometres
and lengths up to several microns. This phenomenon
has been implicated in a variety of pathogenic processes,
including Alzheimer’s and Parkinson’s diseases, Type II
diabetes and Systemic Amyloidoses [1–3]. The associ-
ation with human diseases has largely motivated a long
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standing effort to probe the assembly process and numer-
ous studies have aimed at elucidating the mechanism of
amyloid aggregation [4]. The basic nature of the aggre-
gation reaction has emerged as a nucleation and growth
process [5, 6], where the aggregates are created through
a not well understood primary nucleation event, and can
grow by recruiting further peptides or proteins to their
ends [7, 8]. In this paper we focus on the nature of this
primary step in amyloid nucleation and the fundamental
initial events that underlie amyloid formation.
Amyloidogenic peptides and proteins when in their
non-pathological cellular form can range in the struc-
tures from mainly α-helical, β-sheet and even random
coil, while the amyloid forms of proteins possess a generic
cross-β structure [9–14]. The formation of amyloid is
hence accompanied by marked changes in the conforma-
tions of the peptides and proteins that undergo this pro-
cess. A pertinent question is whether this conformational
change takes place simultaneously with the nucleation
process or whether nucleation takes place first and is then
followed by conformational change. These two possible
scenarios of nucleation have been extensively discussed in
the experimental and theoretical literature [5, 8, 15–19].
We will refer in this work to the two scenarios simply as
the one-step nucleation (1SN), in which the β-sheet en-
riched nucleus forms directly from the solution, and the
two-step nucleation (2SN), where soluble monomers first
assemble into disordered oligomers, which subsequently
convert into a β-sheet nucleus. Disordered oligomers,
ranging in size between dimers and micron-sized parti-
cles, have been observed in some experiments [20–28].
These findings highlight a central question regarding the
role of disordered oligomers in fibril formation: are such
2clusters a necessary step in the process of fibril formation,
or are they just a by-product?
From a biological and biomedical perspective, it is
important to understand the conditions under which
oligomeric clusters form because such species exhibit high
cytotoxicity [1, 29–31]. Indeed, there is strong evidence
that the disordered oligomers, rather than fully-grown
fibrils, are the main pathogenic species in protein ag-
gregation diseases [31–33]. As such, defining the role of
the prefibrillar oligomers during amyloid formation will
be crucial to develop intervention strategies that target
these species [1, 30, 34, 35].
Mutations in the polypeptide sequence and extrinsic
changes in the experimental conditions are known to al-
ter the concentrations of aggregated species, their size
and cytotoxicity [25, 36–39]. For instance, mutations
that increase hydrophobicity of the Alzheimer’s beta pep-
tide Aβ1-42 have a pronounced effect on its aggrega-
tion behaviour and the size distribution of the result-
ing oligomers [23–26, 40], promoting toxicity and ex-
pediting the fibrillization process. In the same spirit,
two extra hydrophobic residues in Aβ1-42 are believed
to contribute to the more pronounced oligomerisation
and faster fibrillization compared to its alloform Aβ1-
40 [24, 25, 40]. Temperature, pH, and concentration of
certain metals also affect oligomerization and pathways
of fibrillization [41–44].
The common feature of above experiments is that they
modify the internal free energy difference between the sol-
uble and the β-sheet forming state, also called the β-sheet
propensity, which has been extensively studied in the lit-
erature [45–48]. However, they also modify interactions
between peptides that aggregate, a crucial contribution
that has not yet been systematically addressed.
In this paper we study the effect of non-specific in-
teractions between peptides on the amyloid nucleation
process. Such non-specific interactions do not depend
on the atomistic details of the amino acids involved, al-
lowing us to address question about amyloid aggrega-
tion and nucleation, using a coarse-grained model. In
particular, generic hydrophobic stretches in the sequence
of Aβ, have been shown to be sufficient to promote ag-
gregation [49, 50]. Mutations of nonpolar residues to
other nonpolar residues had a little or no effect on ag-
gregation, while mutations that reduce charge and/or in-
crease hydrophobicity enhanced it [50, 51]. Furthermore,
atomic force microscopy measurements have shown that
the strength of overall interactions between amyloido-
genic proteins correlates with their tendency to aggre-
gate [52, 53].
We have performed extensive computer simulations
that allow us to observe both the 1SN and the 2SN mech-
anisms. These simulations reveal that 1SN and 2SN can
be viewed as two limits of the same process, something
that several previous studies have suspected [16, 18]. Im-
portantly, we observe that only 2SN is possible at low
peptide concentrations, comparable to the levels that are
found in vivo. Another key observation is that fibril nu-
cleation typically does not proceed via the most preva-
lent oligomeric species, but rather via an oligomer with
a size that is only observed as a result of rare fluctu-
ations. As a consequence, such oligomers will be hard
to capture experimentally, although their presence is re-
quired for nucleation to take place. Our simulations show
that the free energy barrier for fibril nucleation via the
two-step mechanism decreases with increasing strength
of the inter-peptide interactions. Furthermore, the crit-
ical nucleus size in the two-step mechanism is found to
grow with the increase in the peptide concentrations as
well as with stronger interpeptide interactions, which is
in direct contrast with the classical nucleation. These re-
sults imply that weakening the non-specific interactions
between peptide monomers in solution, and thereby si-
multaneously increasing both the free energy barrier for
oligomer formation, and the free energy barrier for pep-
tide conversion at a given oligomer size, may be a crucial
step in preventing amyloid aggregation.
Coarse-Grained Model of an Amyloidogenic
Peptide Supported by Atomistic Simulations. In
view of the experimental evidence that the formation of
peptide oligomers is governed by generic features of the
interactions between monomers [49, 50, 54], we can em-
ploy a simple, coarse-grained, model of an amyloidogenic
peptide. The great advantage of such a model is that
it is sufficiently cheap to allow us to vary inter-peptide
interactions and explore a wide range of peptide concen-
trations. The model should be able to capture both the
formation of amorphous oligomers and the nucleation of
fibrils. Earlier studies [55] have shown that a minimal
model that captures this phenomenology accounts for the
fact that the peptides can be in two states: a soluble state
that can form only disordered oligomers, and a higher
free-energy state that can form β-sheet-like fibrils
The soluble state of the amyloidogenic peptide is mod-
elled as a hard spherocylinder with an attractive patch
at the tip (Fig. 1A). The patch is the source of non-
specific attractions, whose strength is represented by the
parameter ss. Such particles are able to make micellar-
like oligomers, as represented in Fig. 1C, Upper, but not
extended aggregates. The β-sheet forming configuration
is described as a hard spherocylinder with an attractive
side-patch (Fig. 1A). Peptides in the β-state interact
with an interaction strength ββ if their patches point
towards each other. In that case they tend to pack paral-
lel to one another, which leads to the fibril-like structure
(Fig. 1C, Lower). The interaction strength between the
soluble and the fibril-forming state is given by sβ (Fig.
1A). In our Monte Carlo simulations a soluble protein can
convert into the β-prone state every simulation step with
some small probability that mimics slow conversion of the
soluble peptide into the β-prone configuration. The con-
version, apart from being kinetically slow, is also thermo-
dynamically unfavourable, which reflects the loss of the
conformational entropy of the β-prone form compared to
the soluble form [14]. Hence we penalize every conver-
sion from the soluble to the β-form with a change in the
3excess chemical potential of ∆µ = 20kT , where k denotes
Boltzmann’s constant. This value is chosen to reflect the
fact that amyloidogenic proteins are typically not found
in the β-sheet conformation in solution [54, 56]. With
respect to the current body of work on the importance
of the β-sheet propensity, this places our model in the
range of proteins with small- to mid-β-propensity, such
as Aβ. Further details of the coarse grained model can
be found in the Supporting Information I.
To obtain an estimate of the interaction parameters
ββ , sβ and ss, we carried fully atomistic simulations in
the system of the Aβ1-42 peptide in explicit water, and
used umbrella-sampling to determine the three possible
pair-interactions. Details of the simulation procedure are
explained in SI Text, section II and Fig. S1. As expected,
the interaction between two peptides in the hairpin con-
formation packed in the β-sheet, reflecting the ββ inter-
action, is the strongest (−15kT ), as shown in Fig. 1B.
To obtain an estimate of the interaction between the sol-
uble and the β-prone peptide, we constrained one of the
peptides to be in the U-turn shape of a β-hairpin con-
figuration and sampled its interaction with the random-
coil peptide. Although the atomistic properties of the
isolated β-prone peptide are still unknown, our purpose
here is to use a conformation that can easily act as a
platform for fibril assembly. We find that the interaction
energy of this s−β complex at the shortest sampled dis-
tance is −8.7 kT . The interaction between the peptides
in random coil conformation is the smallest of the three
(−5.4 kT ), but still clearly attractive. In our model, the
strength of this attractive interaction is represented by
ss. It is important to note that the shortest sampled in-
terpeptide separation in each of the three cases is limited
by the sum of the peptides’ radii of gyration. Of course,
it is an oversimplification to try to capture the interac-
tion energy between two complex, fluctuating peptides
by a single number. However, we argue that the rela-
tive interaction strengths that we compute in our atom-
istic simulations are indicative of the relative strengths
of the interactions in the first steps of assembly. We use
the atomistic simulations mainly to justify why, in our
coarse-grained model, we choose the following ordering of
interaction strengths: ββ > sβ > ss. An additional set
of umbrella simulations was performed on the A2V mu-
tation of Aβ42, which is reported to be responsible for
early-onset Alzheimer’s disease [57], with the purposes
of evaluating the relative strengths of interactions for an
additional system and further supporting the choice of
energy scale in the coarse-grained model. The Aβ42-
A2V simulations show the same trend for the interaction
strengths as the wild-type (WT), with ββ > sβ > ss
(14.6, 5.9 and 4.3kT respectively (Fig. S2 (D)). (We do
not discuss implications of this mutation on the mech-
anism underlying the A2V substitution in Aβ fibrillo-
genesis. To accurately compare it to the wild-type, we
would also need to asses the free energy barrier for the
β-conversion associated with both variants, which is not
within the scope of this work.)
1SN Vs. 2SN. Our Monte Carlo simulations al-
low us to study amyloid nucleation pathways over a
range of peptide concentrations and interpeptide inter-
action strengths. A tentative phase diagram is shown
in Fig. 2A. When interactions between peptides in the
solution are sufficiently strong (ss & 5kT ), disordered,
micellar-like oligomers are formed before the observation
of elongated fibrils. These oligomers exist in the solu-
tion for a long time before transforming into a β-sheet
nucleus through a series of single-peptide conversions,
during which each converted peptide is in contact with
other random coils within the aggregate. This two-step
mechanism (2SN) is often referred to in the literature
as the nucleated-conformational conversion (NCC), and
was observed both for Aβ peptides [18] and prion pro-
teins [17] under certain experimental conditions. The
β-sheet protofibril can further grow by either addition
of monomers from the solution or merging with another
oligomer. The preferred mode of growth will depend on
the exact conditions: at lower concentrations and lower
ss-values, the system is well below the critical micelle
concentration, and there will be many more monomers
than oligomers in solution [58]. In that case, the growth
will mainly be through monomer addition [17]. Above
the critical micelle concentration, most of peptides will
be incorporated within oligomers, and few monomers will
remain in solution. In that case, the addition of disor-
dered oligomers at the end of the growing fibre becomes
the more probable fibril growth mechanism [18].
Our atomistic simulations show that the attractions
between soluble peptides originate mainly from polar in-
teractions, with some participation of hydrogen-bonding
(Fig. S2 B and C). Recent molecular simulations support
this observation and indicate that the polar N-terminal
region can act as a catalytic region that initiates and
accelerates assembly of Aβ peptides [59, 60].
If the interactions between peptides are weak (ss .
5kT ), we observe that fibril nucleation can happen only
when the peptide concentration is high - above 2 mM
in our case. At high concentrations, random fluctuations
can push monomers close to each other, and a nucleus can
be born from the solution in a single step without any no-
ticeable preceding aggregate (1SN). This event is followed
by the rapid growth by monomer addition and sometimes
referred to as the nucleated-polymerisation (NP) [5, 8].
It is important to point out that the lifetime of the disor-
dered oligomers is the key feature that distinguishes this
mechanism from the 2SN route discussed above. Fig.
2B, Left shows the representative snapshots during the
1SN nucleation process. Closer inspection reveals that,
because of random fluctuations, several soluble peptides
interact with each other and other peptides that can
convert to the β-prone state because of the stabilizing
interaction with the soluble peptides. Interpeptide in-
teractions are crucial even in this case, but the event is
transient: it does not require the presence of long-lived
oligomers. (Long-lived in our simulations means that,
after oligomers form, they tend to stay stable for most
4of the simulation time.) We should emphasize that the
cross-over from 1SN to 2SN is not abrupt, and in the
regime of high peptide concentrations and intermediate
interactions, one can observe nucleation from short-living
oligomers, which exhibits features of both limits.
It is worth adding that at much higher peptide con-
centrations and interpeptide interactions than the ones
reported here, kinetically arrested amorphous aggregates
can be observed [61, 62]. We did not study this region,
since we focus on more physiologically relevant concen-
trations and interaction values.
Nucleation at Low Peptide Concentrations. The
most relevant regime for amyloidogenic peptides under
physiological conditions is the regime of low peptide con-
centrations (micro- and nano-molar). Our simulations
clearly show that in this regime 1SN is extremely un-
likely - so much so that we did not observe a single 1SN
event in our longest (109 Monte Carlo steps) simulation
runs. The explanation is simple: in this regime, the prob-
ability of a random encounter of enough monomers to
initiate fibril nucleation is completely negligible. At low
peptide concentrations nucleation can only be achieved if
there are appreciable attractive interactions between sol-
uble monomers. Such nonspecific attractions favor the
formation of long-lived peptide clusters in which subse-
quent fibril nucleation can take place. For instance, at a
concentration of c ∼ 70µM , we observe fibrils above the
threshold of ss & 8kT . In this case, nucleation originates
inside oligomers that form only rarely but are relatively
long-lived. Fig. 2B, Right shows an example of the 2SN
mechanism that we observe. Direct experimental obser-
vation of the first stages of 2SN may be challenging as the
concentration of the oligomers is very small. However,
our simulations suggest that it should be straightforward
to obtain indirect evidence of the 2SN mechanism: pro-
teins that do not attract in solution, and cannot form
prefibrillar clusters, are very unlikely to form fibrils at
low concentrations.
Role of Oligomers in the Nucleation Process:
Free Energy Analysis. Non-specific attractions be-
tween soluble peptides favour the formation of relatively
long-lived oligomers. The existence of oligomers lowers
the nucleation barrier for the subsequent fibril forma-
tion because, as our atomistic simulations show, the sβ-
interaction is more favourable than the ss-interaction,
and the ββ-interaction is more favourable still. Hence,
the energetic price to pay for the conversion from the s-
state to the β-state inside an oligomer is compensated
by the gain in interaction energy between the peptides.
Increased number of hydrophobic contacts between the
β-form and the soluble peptide is the reason why the
sβ-interaction is favourable (Fig. S2A). This enhanced
hydrophobic interaction stabilizes the amyloidogenic β-
form when in contact with other random coils within a
disordered aggregate. To quantify this effect, we per-
formed Monte Carlo umbrella sampling simulations to
compute the free energy barrier for fibril formation in-
side an oligomer in our coarse-grained system. Details
of the simulation method are given in SI Text, section II
and Fig. S1.
We find that the first conversion step (i.e. the one in-
volving the first soluble monomer converting to a β-form
within the oligomer) determines the height of the free en-
ergy barrier. The finding that the first s − β conversion
has the highest free energy cost is not too surprising: in
this process, the conformational entropy of one random
coil is lost, and there is only a small gain caused by inter-
actions of the β-form with the remaining random coils.
As soon as the second monomer converts to the β-form, a
β-sheet interaction is established, which is enthalpically
very favourable because of the increase in hydrophobic
contacts and hydrogen bonds (see Fig. S2 A and C). Ev-
ery subsequent contact between the β-sheets lowers the
free energy of the oligomer even more, thus the rate lim-
iting step is the formation of the first β-form peptide.
Hence, in our simulations the critical nucleus for fibril-
isation is an oligomer (of yet undetermined size) with
exactly one converted peptide. The smallest possible fib-
ril is then made of two β-peptides, while in practice such
small fibrils quickly continue growing.
Our umbrella sampling simulations allow us to calcu-
late the free energy change for converting one peptide
into the β-state within an oligomer of the size N , when
varying the ss peptide interactions (Fig. 3A). We find
that the barrier for the conversion ∆Fc(N) systemati-
cally decreases with increasing size of the oligomer for a
fixed ss interaction. Such behaviour is to be expected
as the number of possible sβ-interactions increases with
the oligomer size. Of course, the effect of the oligomer
size eventually saturates when the maximum number of
geometrically allowed interactions is reached.
Not surprisingly, the nucleation barrier also systemat-
ically decreases with stronger interpeptide interactions.
This finding can be seen to emerge from the assumption
that sβ shifts together with ss: strong ss is compen-
sated for by strong(er) sβ . To inspect the origin of this
correlation, we measured ∆Fc(N) for different values of
s-β stabilizations (Fig. S3) and found that the nucleation
barrier drops down dramatically with stronger sβ inter-
action. This effect is likely to contribute to the higher
rate of nucleation of Aβ1-42 compared to Aβ1-40 [63],
and peptides with hydrophobic mutations compared to
their respective WTs. However, at very high values of ss
(over 10 kT ), the oligomer reorganization might become
very slow, and the process can be kinetically arrested.
Despite the fact that the exact number of converted pep-
tides that give rise to nucleation can be dependent on
the simulation model or the protein under study, and is
governed by the ββ/ss ratio, the trends described here
should be general.
Two Competing Free Energy Contributions
Cause Nonclassical Scaling of the Critical Nu-
cleus Size. The overall nucleation barrier for fibril
nucleation is the sum of two contributions: the first
is the free-energy cost of forming an oligomer of size
N . The second is the free energy cost of nucleating
5a fibril in such an oligomer. Both free energy barri-
ers depend on N . We can compute ∆Fo(N), the free
energy barrier for the formation of an oligomer of size
N from measurements of the oligomer size distribution,
P (N), using ∆Fo(N) = −kT lnP (N).Examples of P (N)
measurements for several values of c and ss are shown
in Fig. S4. For dilute solutions of clusters, P (N)
is of the form P (N) ∼ e−∆f(N)/kT cN , where ∆f(N)
is a concentration-independent free-energy and c is the
monomer concentration. Clearly, for low values of c,
∆Fo(N) will grow rapidly with cluster size, which has
important consequences for the overall behaviour of the
free-energy barrier for fibril nucleation: for low monomer
concentrations, the lowest overall nucleation barrier will
correspond to nucleation of a fibril in a relatively small
oligomer. For higher concentrations, fibril nucleation in
larger oligomers will dominate. Fig. 3B shows an exam-
ple of the various contributions to the fibril nucleation
barrier for one specific choice of the monomer concen-
tration and the value of ss. The shift of the nucleation
barrier with monomer concentration is shown in Fig. 4A,
while the arrows indicate the respective dominant nu-
cleus sizes. Fig. 4B shows the variation of the nucle-
ation barriers with the non-specific monomer-monomer
interaction (ss). Fig. 4B clearly shows that, all other
things being equal, stronger non-specific interactions be-
tween soluble peptides tend to decrease the fibril nucle-
ation barrier very substantially. The underlying reason is
that ∆Fo(N) decreases strongly with increasing ss. We
stress that the nucleation of fibrils cannot be described
by classical nucleation theory: that theory would predict
that the size of the critical nucleus would grow both with
a decrease in concentration and in the inter-peptide inter-
actions. The explanation is that, unlike the classical nu-
cleation case, we are always working in the regime where
the condensed phase of the soluble peptides is thermody-
namically unstable. Hence large clusters are disfavoured,
in particular at low concentrations. Yet, fibril nucleation
must proceed via a cluster, and that process is easier in
large clusters (if they can form). It is the compromise be-
tween these two trends that lead to the observed variation
of the critical nucleus size with monomer concentration
and ss.
Discussion and Conclusions. Our numerical study
reveals the crucial effect of non-specific inter-peptide at-
tractions on the pathways of amyloid aggregation. We
find that for peptides that do not attract, the classical
one-step nucleation mechanism is possible, but only at
very high peptide concentrations. At low peptide con-
centrations, attractive inter-peptide interactions are es-
sential for fibril formation. Nucleation then inevitably
takes place through a two-step mechanism where the for-
mation of disordered oligomers preceded fibril nucleation.
Although direct measurements of such non-specific inter-
actions have been challenging to achieve, the determi-
nation of second virial coefficients with advanced light
scattering techniques [64] is a promising avenue to ac-
cess these values for amyloidogenic peptides and their
mutants in solution.
We recall that this study focused on peptides with
low- to mid-β-propensity (∆µ = 20kT ). If the β-state
were stable and could exist in solution, oligomers would
not be needed to aid nucleation and the 1SN scenario
would become more probable. However, the available
experimental data suggest that the β-state is usually not
present in solution, at least not for the Aβ peptide. It
has been observed that mutants that further decrease β-
sheet propensity (such as the E22GAβ) exhibit enhanced
oligomer formation over the wild-type [51, 65, 66], which
is in agreement with our findings. Our coarse-grained
model, although supported by atomistic simulations, is
of course highly simplified as we consider only two pep-
tide states. In reality, we expect there to be several in-
termediate conformations on the pathway between the
soluble and the β-form. Qualitatively, the key physical
behaviour originates from the fact that the “mixed” in-
teraction energy sβ is intermediate between that of the
pure soluble and the β-form. As such, the present re-
sults are expected to generalise to other coarse graining
schemes which exhibit this property, including ones with
more than one intermediate state.
In this framework, oligomers play a dual role. Disor-
dered oligomers not only help peptides meet each other,
but also create an environment that facilitates the con-
version of monomers into the β-form. We stress that
whilst the oligomers that form due to attractive non-
specific interactions are rare (and therefore hard to ob-
serve directly), their formation is a crucial on-pathway
step in the amyloid formation process for peptides whose
β-competent state is not particularly stable. Similar two-
step nucleation processes involving amorphous precursors
have been identified in very different physical phenom-
ena, such as protein crystal nucleation [67], nucleation of
sickle-cell haemoglobin polymers [68] and biomineraliza-
tion [69]. The surprising finding of the present work is
that at realistic (i.e. low) peptide concentrations, fib-
ril formation must proceed via an intermediate amor-
phous oligomer and that this pathway leads to highly
non-trivial predictions for the dependence of the critical
nucleus size and nucleation barrier on monomer concen-
tration and inter-peptide interaction. Since oligomeric
species formed under such conditions consist predomi-
nantly of non-beta structures, it is interesting to specu-
late that nature might have evolved a portfolio of chap-
erones to target specifically both the non-beta as well as
the conventional beta aggregated forms to curtail patho-
logical aggregation. Recent evidence suggests that such
a situation might indeed occur for extracellular chaper-
ones [70, 71]. Whilst the present simulations focused on
the Aβ1-42 peptide, we expect aspects of the mechanism
proposed here to be applicable to other amyloid proteins,
such as the prion protein or α-synuclein. The conforma-
tional change from the soluble into the β-prone state is
a ubiquitous feature underlying the amyloid aggregation,
and the importance of disordered oligomers could be of
a more general nature.
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FIG. 1: Possible interactions in the system. (A, Left) Two spherocylinders representing the soluble peptides interact via their
attractive tips (blue). The interaction strength is given by ss. (A, Center) Spherocylinders in the β-form interact via their
side-patches (red). The strength of this interaction is ββ . (A, Right) The interaction between the soluble peptide and the
β-competent form, given by sβ . Underneath each coarse-grained representation is its atomistic realization for the case of
the Aβ1-42 peptide. Snapshots are taken at the shortest distance of the Molecular Dynamics umbrella sampling at 10ns. (B)
Potential of mean force (PMF) for the pair interactions in the Aβ1-42 system used to guide coarse-grained simulations. The red
curve represents the interaction between two peptides in the β-form, the blue curve is the interaction between the random-coil
peptides, while the black line is the interaction between the random-coil peptide and the peptide kept in the β-prone form. (C )
Representative snapshots before the nucleation occured, and at the end of the simulation run. (Upper) Disordered oligomers
formed by peptides in their soluble form, red circle magnifies such an oligomer. (Lower) Amyloid-like fibrils formed by peptides
in the β-sheet-competent form. For visual clarity, the red attractive patch in the β-form is depicted spanning the whole length
of the spherocylinder body.
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FIG. 2: Mechanism of amyloid nucleation. (A) Tentative phase diagram. At low concentrations and low interpeptide interactions
no nucleation was observed (black circles). The one-step mechanism is possible only at low interpeptide interactions and high
concentrations (blue triangles). In any other case the nucleation proceeded through the two-step mechanism (magenta asterisks).
All points are collected for sβ = ss + 1kT . The dashed lines are a guide to the eye. (B) Pre- and postnucleation snapshots
for two points in the phase diagram. (Left) 1SN case, c = 1.8mM, ss = 4.5kT . The red circle zooms into the area where
nucleation happens. (Right) 2SN case at low peptide concentration, c = 72µM, ss = 8kT . The nucleating oligomer is circled
in red in the first snapshot and magnified in the rest of the snapshots.
(a) (b)
FIG. 3: (A) The free energy barrier ∆Fc for conversion of one random-coil peptide into the β-form within a disordered
oligomer of the size N , for various values of interpeptide interaction. From top to bottom ss = 3, 4, 5, 6, 8, 10 kT . In all cases
sβ = ss + 1kT (B) Partition of the free energy barrier for nucleation from solution. Red line and red squares: Free energy for
oligomerization, ∆Fo(N), obtained from the oligomer-size distribution P (N) (shown in inset) at c = 2.17mM and ss = 6kT .
The blue line and blue circles show the free energy for conversion of one peptide into the β-prone state within an oligomer of
size N , ∆Fc(N), for ss = 6kT and sβ = 7kT . Note that the blue line in B corresponds to the blue line in A. Violet line and
violet diamonds: Free energy barrier for formation of a critical nucleus from solution, ∆F ∗, at c = 2.17mM and ss = 6kT ,
obtained as ∆F ∗ = ∆Fo(N) + ∆Fc(N).
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FIG. 4: Free energy barrier for nucleation from solution. (A) For constant interpeptide interaction and various peptide
concentrations, ss = 4kT and all peptide concentrations are expressed in mM. (B) For various interpeptide interactions
(expressed in kT )and constant peptide concentration c = 0.72mM. In all cases sβ = ss+1kT . Arrows indicate critical nucleus
sizes for several chosen parameters.
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SI Text
I. Coarse-grained Simulations: Methods
Each spherocylinder is σ = 2nm wide and L = 4σ =
8nm long. The hard core repulsion forbids for any dis-
tance between any two spherocylinders to be smaller than
σ. The interaction between two peptides in the soluble
form is implemented as:
Vss(r) =
−ss
(σ
r
)6
if r ≤ 1.5σ
0 if r > 1.5σ
(1)
where r is the distance between the centers of the at-
tractive tips located at the spherocylinders’ ends. An
attractive patch is added only at one spherocylinder pole
to ensure formation of finite aggregates like those ob-
served in experiments. This potential is reminiscent of a
coarse-grained model for lipids [1]. Because the center of
the patch is only at one tip, there is an effective orien-
tational dependence that is controlled by the cut-off of
the tip-to-tip attraction. This potential drives the forma-
tion of spherical-like micelles, where tips of participating
peptides are in contact in the micelle center. There is
no other explicit angular dependence, and any angle be-
tween peptides in the s-state whose attractive tips are in
contact are equally favourable.
The attractive side-patch of the β-sheet forming con-
figuration is Lp = 0.6L long and spans an angle of 180
◦.
If two patches face each other their interaction is:
Vββ(r) =
{
−ββcos2(φ)− ββ
(σ
r
)
if d ≤ 1.5σ
0 if d > 1.5σ
(2)
where φ is the angle between the axes of the particles,
d is the shortest distance between the axes of the patches,
and r is distance between the centers of the patches. The
first term controls that peptides in the β-forms pack par-
allel to each other, mimicking the hydrogen-bond inter-
actions between β-sheets, while the second term ensures
compactness of the fibrils [2–4]. In this study we choose
ββ = 30kT [5, 6]. Aggregation of patchy-spherocylinders
has been studied in details in our previous work [7]. The
cross-interaction between the soluble and the β-sheet-
forming configuration is designed like:
Vsβ(r) =
{
−sβ if d < 1.5σ
0 if d > 1.5σ
(3)
where d is the shortest distance between the centre of
the attractive tip and the axis of the β-patch. This inter-
action is also effectively orientation-dependent, which is
controlled by the cut-off of the potential, and the angular-
width of the β-patch.
We simulate the system of 600 peptides in a cubic box
at volume fractions 0.06, 0.05, 0.04, 0.03, 0.025, 0.02,
0.01, 0.005 and 0.001, corresponding to peptide concen-
trations of 4.34 mM, 3.61 mM, 2.89 mM, 2.17 mM, 1.81
mM, 1.45 mM, 0.72 mM, 0.36 mM and 72 µM respec-
tively. Each Monte Carlo run was at least 106 steps long.
To obtain the free energy barrier ∆Fc(N) for conver-
sion of one soluble peptide into the β-form within an
oligomer of a size N , we restrain the centers of attractive
tips of N monomers to stay within a spherical space of ra-
dius 5σ. In this way, monomers are kept in a micellar-like
conformation, while having enough freedom to find their
preferential orientation with respect to each other. A bi-
asing harmonic potential is then applied, which ensures
that the number of monomers in the β-form oscillates
between 0 and 1. Regarding the value of the harmonic
spring that is applied, we scanned a wide range of values
in each case, until we found the one that equally well
samples both sides of the barrier (the side where all pep-
tides are in the s-state, and the one where exactly one
peptide has converted into the β-state).
The free energy change for oligomerisation is obtained
from simulating 600 monomers in a soluble form and col-
lecting the oligomer-size distribution P (N). The free en-
ergy for formation of an oligomer of the size N is then
∆Fo(N) = −logP (N) + F 0, where the zero-energy level
F 0 is attributed to free monomers in the solution.
Finally, the free energy barrier to nucleate from the
solution is ∆F ∗(N) = ∆Fo(N) + ∆Fc(N).
II. Umbrella Sampling of Aβ1-42 Interactions:
Methods
The starting conformation of the atomistic simulation
is based on the 3D model of the Aβ protofibril consist-
ing of five peptides (PDB 2BEG)[8]. The residues 1 to
16 were added to the Aβ17-42 dimer from this structure
using the building tool in Pymol in a disordered confor-
mation with randomly chosen [ϕ,ψ] dihedral values.
Simulations were performed using the Amber99SB-
ILDN force field[9] and the TIP3P water model[10] in
the GROMACS 4.6.3 package[11] with Ewald summation
for long-range electrostatic interactions[12]. The LINCS
algorithm[13] was used to constrain all bond lengths to
their equilibrium values and a time step of 2.0 fs was set.
To describe the β-β interaction, dihedral restraints
were applied on the sequence 17-42 forming the hairpin
of the dimer, with a force constant of 200 kJmol−1rad−2.
These restraints were used to preserve the fibril-
2competent state, and prevent it from unfolding as the
monomers are separated and the inter-chain hydrogen
bonds are broken. In order to generate the disordered
starting conformation for the other two types of inter-
actions (soluble-β and soluble-soluble), a molecular dy-
namics simulation was performed at 500 K from the built
conformation of Aβ1-42 for 1000 ps. Each Aβ dimers (β-
β, s-β, s-s) were solvated in a periodic box of 1,512 nm3
with approximately 50,300 water molecules and a salt
concentration of 0.1 M. All three systems were subject
to a minimization using the steepest descent algorithm
and Molecular Dynamics (MD) simulations at constant
volume and temperature for 100 ps, with position re-
straints on all heavy atoms, in order to equilibrate the
solvent molecules. This step was followed by 100 ps of
MD simulations in the Canonical ensemble without po-
sitional restraints. The systems were then simulated for
a last step of 100-ps long MD in the isothermal-isobaric
ensemble. The Nose´-Hoover thermostat[14, 15] was ap-
plied for temperature control and the Parrinello-Rahman
barostat[16] for pressure control. The temperature and
pressure of the simulations were set to 300 K and 1 bar,
respectively.
The resulting unsolvated conformation of Aβ peptides
were then used to prepare the umbrella simulations start-
ing conformations. The chains were separated along the
z-axis of the center of mass vector between them. The
initial distances were of 0.85, 1.2 and 2 nm for the β-β,
soluble-β and soluble-soluble conformations, respectively.
All starting states were then solvated in the same condi-
tions described above in a periodic of box of 1,512 nm3,
followed by a 100-ps position restrained simulation and
a total of 200 ps of unrestrained equilibration.
Umbrella sampling simulations were then performed for
10ns using a spring constant of 3000 kJmol−1nm−2 for
each three sets of Aβ conformations, using as a reaction
coordinate the center of mass separation along the z-axis.
It is important to note that the shortest separation for the
umbrella simulations of the disordered conformation are
limited by the radius of gyration for each chain, prevent-
ing the shortest sampled distance to be smaller than the
sum of the respective radii of gyration. The Potentials of
mean force (PMFs) were calculated using the Weighted
Histogram Analysis Method (WHAM) as implemented
in GROMACS[17] without the first ns for equilibration
purposes.
The number of atomic hydrophobic and polar contacts
and hydrogen bonds were computed using GROMACS
analysis tools. The same simulation protocol was used
to perform the umbrella simulations of the A2V variant
of Aβ42.
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4Phase space exploration around εss
obtained from atomistic simulations, 
and at different concentrations, to gain 
insight into 1SN vs 2SN (Fig. 2)
Umbrella sampling of nucleation 
barrier within oligomers (ΔFc) at 
different εss and N (Fig. 3A)
Obtaining P(N) for oligomers from the 
solution of s-state at different εss and 
c to obtain ΔFo  (Fig. 3B and Fig. S4) 
Nucleation barrier for 2SN
 ΔF* = ΔFc + ΔFo
(Fig. 3B, Fig. 4A and 4B)
Structure preparation
1. Equilibrating starting dimer configuration
2. Separating chain 1 and 2
3. 200 ps equilibration
Umbrella sampling of interactions 
between chains 1 and 2 at various 
distances (10 ns)
WHAM on the last 9 ns to obtain εss,
εsβ and εββ (Fig. 1B) and other 
analysis  (Fig. S2)
Conclusion
εss < εsβ < εββ
Atomistic Simulation
Coarse-grained Simulation
Setting  εss < εsβ < εββ
S 1: Chart of the computational workflow carried out in this paper.
5S 2: The average number of contacts between (A) atoms of hydrophobic residues, (B) atoms of polar residues and
(C) the average number of hydrogen bonds, calculated for each umbrella simulation as a function of the reaction
coordinate for all three pair-interactions: β − β (red line and red squares), soluble-β (black line and black squares),
soluble-soluble (blue line and blue squares). (D) Potential of mean force (PMF) for the pair interactions in the A2V
mutant of the Aβ1-42 system, illustrating the interaction between two peptides in the β-form (red line), the
interaction between the soluble peptide and the peptide kept in the β-prone form (black line) and the interaction
between the soluble peptides (blue line).
S 3: The free energy barrier ∆Fc for conversion of one random-coil peptide into the β-form within a disordered
oligomer of the size N , for various values of sβ interaction parameter. From top to bottom sβ = 6, 7, 8, 10kT . The
soluble-soluble interaction is kept constant at ss = 6kT .
6S 4: Oligomer size distribution P (N) for three combinations of c and ss. Note that for all three cases most of the
peptides are in the monomeric form, and the system is below the critical micelle concentration.
